1.	Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: D7913L00077, NCT01579630
2.	Phase III Randomized Study of Prophylactic Cranial Radiotherapy in Patients With Advanced Non-Small Cell Lung Cancer That is Responsive to Gefitinib or Erlotinib Hydrochloride. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Prevention, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: KROG-4-2008-0276, 4-2008-0276, NCT00955695
3.	Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001) Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ZhejiangCH06, NCT01158170
4.	Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation Phase: Phase III Type: Treatment Status: Active Age: 18 to 74 Sponsor: Other Protocol IDs: C-TONG 1104, NCT01405079
5.	A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D791LC00001, NCT01544179
6.	ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DP312804, NCT01774721
7.	Hydroxychloroquine and Gefitinib to Treat Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: NS 01/03/08, 2008/00196, NCT00809237
8.	Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NCCCTS-09-433, NCT01027676
9.	Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GECP10-03, 2010-024178-21, NCT01513174
10.	Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000582623, YONSEI-4-2006-0136, ZENECA-YONSEI-4-2006-0136, 4-2006-0136, NCT00616499
11.	Phase II Prospective Study of Paclitaxel and Carboplatin in Combination With Intermittent Gefitinib in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CIH-CAMS-CHL-020, CHL-020, NCT01024712
12.	Erlotinib Versus Gefitinib in Advanced Non Small Cell Lung Cancer With exon21 Mutation:A Randomized Trial Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: C-TONG0901, NCT01024413
13.	Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Iressa combined with Pem/Cis, NCT01192243
14.	Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer Phase: Phase II Type: Treatment Status: Active Age: 70 to 85 Sponsor: Other Protocol IDs: ZhejiangCH10, NCT01291823
15.	Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-07-252, NCT01312337
16.	Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CS-S10-09, NCT01391260
17.	Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib Phase: Phase II Type: Diagnostic, Tissue collection/Repository, Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: P01425, 2010-023355-29, 11/H0304/8, NCT01405846
18.	LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Phase: Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.123, 2011-001814-33, NCT01466660
19.	A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14034, H3E-CR-JMIT(a), NCT01469000
20.	Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: SVH-1, NCT01485809
21.	Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 4-2011-0662, NCT01498562
22.	Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: NCCCTS-11-581, NCT01502202
23.	First Line Gefitinib by FDG-PET Metabolic Response Phase: Phase II Type: Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: AMC 2011-0858, NCT01510990
24.	Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913L00138, EUDRACT n 2011-005157-31, NCT01530334
25.	Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IFCT-1003, NCT01556191